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Abstract
Background: The number of people with cardiovascular disease (CVD) and diabetes mellitus type
2 (T2DM) is growing rapidly. To a large extend, this increase is due to lifestyle-dependent risk
factors, such as overweight, reduced physical activity, and an unhealthy diet. Changing these risk
factors has the potential to postpone or prevent the development of T2DM and CVD. It is
hypothesized that a cognitive behavioral program (CBP), focused in particular on motivation and
self-management in persons who are at high risk for CVD and/or T2DM, will improve their lifestyle
behavior and, as a result, will reduce their risk of developing T2DM and CVD.
Methods: 12,000 inhabitants, 30-50 years of age living in several municipalities in the semi-rural
region of West-Friesland will receive an invitation from their general practitioner (n = 13) to
measure their own waist circumference with a tape measure. People with abdominal obesity (male
waist ≥ 102 cm, female waist ≥ 88 cm) will be invited to participate in the second step of the
screening which includes blood pressure, a blood sample and anthropometric measurements.
T2DM and CVD risk scores will then be calculated according to the ARIC and the SCORE
formulae, respectively. People with a score that indicates a high risk of developing T2DM and/or
CVD will then be randomly assigned to the intervention group (n = 300) or the control group (n
= 300).
Participants in the intervention group will follow a CBP aimed at modifying their dietary behavior,
physical activity, and smoking behavior. The counseling methods that will be used are motivational
interviewing (MI) and problem solving treatment (PST), which focus in particular on intrinsic motivation
for change and self-management of problems of the participants. The CBP will be provided by
trained nurse practitioners in the participant's general practice, and will consists of a maximum of
six individual sessions of 30 minutes, followed by 3-monthly booster sessions by phone. Participants
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BMC Endocrine Disorders 2008, 8:6 http://www.biomedcentral.com/1472-6823/8/6in the control group will receive brochures containing health guidelines regarding physical activity
and diet, and how to stop smoking. The primary outcome measures will be changes in T2DM and
CVD risk scores. Secondary outcome measures will be changes in lifestyle behavior and cost-
effectiveness and cost-utility ratios. All relevant direct and indirect costs will be measured, and
there will be a follow-up of 24 months.
Discussion: Changing behaviors is difficult, requires time, considerable effort and motivation.
Combining the two counseling methods MI and PST, followed by booster sessions may result in
sustained behavioral change.
Trial registration: Current Controlled Trials ISRCTN59358434
Background
Partly because of the ageing population, and partly due to
changes in lifestyle and the resulting epidemic of obesity,
there is an increasing percentage of people with diabetes
mellitus type 2 (T2DM) and cardiovascular diseases
(CVDs) in the general population. With a prevalence of
475,000 patients with diabetes and 65,000 new cases each
year, diabetes mellitus is one of the most widespread
chronic diseases in the Netherlands [1]. CVD is a major
cause of disability and mortality in Western countries, and
is responsible for one fifth of all disability-adjusted life
years [2].
To a large extend, T2DM and CVD are caused by lifestyle
dependent risk factors, such as overweight, reduced phys-
ical activity, smoking and an unhealthy diet [3-5]. Chang-
ing these risk factors has the potential to postpone or
prevent the development of T2DM and CVD.
People who are overweight or obese often have a cluster
of risk factors for T2DM and CVD, and the risk increases
progressively as their body mass index (BMI) increases
[6]. Apart from overall obesity, fat distribution is an
important risk factor for T2DM and CVD [7]. Waist cir-
cumference reflects the magnitude of abdominal adipose
tissue deposits as well as total fat mass, and thereby com-
plements BMI in the evaluation of obesity-associated
T2DM and CVD risk [8,9]. It is considered to be a good
measure with which to identify persons with an increased
risk of developing T2DM and CVD [10-12].
The Diabetes Prevention Program Research Group have
shown that intensive lifestyle interventions that encour-
age people to achieve and maintain weight-loss are effec-
tive in lowering the incidence of T2DM [13]. In the
Finnish Diabetes Prevention Study, a lifestyle intervention
in middle-aged, overweight persons resulted in a 58%
reduction or postponement of the overall incidence of
diabetes [14]. A Dutch RCT showed that a lifestyle-inter-
vention program according to general recommendations
(i.e. regular dietary advice, and stimulation to lose weight
and to increase physical activity) was effective and
induced beneficial changes in lifestyle, which improved
glucose tolerance in subjects with impaired glucose toler-
ance [15].
A wide variation of lifestyle interventions are reported in
the literature. Components of interventions that have
been found to be effective are: goal-setting [16], programs
specifically tailored to the participants [14,17], the use of
written materials [14,18], and continued subject-therapist
contact, whether in person or by telephone, mail or e-mail
[19]. Furthermore, effective interventions included those
based on behavioral or cognitive-behavioral strategies, as
opposed to health education or instruction alone [18-21].
Theoretical background
A theory that has been proven useful for the development
of behavioral interventions is the theory of planned
behavior (TPB) [22,23]. The TPB helps us to understand
how energy balance-related behavior is mediated by cog-
nitive constructs [24]. According to the TPB, human
action is guided by three kinds of considerations: a)
behavioral beliefs: beliefs about the likely consequences
of the behavior and the evaluation of these consequences;
b) normative beliefs: beliefs about the normative expecta-
tions of others and the motivation to comply with these
expectations; c) control beliefs: beliefs about the presence
of factors that may facilitate, or may impede the perform-
ance of the behavior, and the perceived power of these fac-
tors. These beliefs can lead, respectively, to a favorable or
an unfavorable attitude towards a certain behavior, per-
ceived social pressure, and perceived behavioral control,
and in combination they determine behavioral intention.
Finally, given a sufficient degree of actual control over the
behavior, people are expected to carry out their intentions
when the opportunity arises.
Leventhal's theory of self-regulation proposes that indi-
viduals construct schematic representations of illness and
health-threatening conditions according to the concrete
and abstract sources of information that are available to
them [25]. The theory starts with the premise that individ-
uals are active problem-solvers. They make sense of aPage 2 of 11
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representations of the threat, which, in turn, determine
how they respond. Health professionals such as nurse
practitioners can be sources of information. The theory
also assumes that a discrepancy between a person's goal or
expected outcome and what exists (the actual situation)
will motivate the person to take action and to reduce this
ambivalence. Feedback on the discrepancy motivates a
person to become actively engaged by attending to stimuli
and making efforts to find a way to overcome the discrep-
ancy between what is expected or desired and the present
state [26].
Cognitive behavioral program
The cognitive behavioral program (CBP) applies several
components of both the TPB and the theory of self-regu-
lation: The counseling techniques that are used in the
intervention are motivational interviewing (MI) and
problem-solving treatment (PST). MI aims to reinforce the
attitude and the behavioral intention according to the
TPB, and induces the ambivalence described in the theory
of self-regulation. PST will be used to support the partici-
pant in finding ways to overcome this discrepancy. A fur-
ther aim of the PST is to strengthen the participant's
perceived behavioral control and to provide the tools to
overcome barriers that hinder a structural change in life-
style behavior.
MI is a client-centered counseling method with which to
elicit behavioral change by helping people to explore and
resolve ambivalence in a respectful counseling atmos-
phere [27]. It is a well-known method of counseling, and
is considered to be a useful intervention strategy in the
treatment of lifestyle problems [28]. The therapeutic rela-
tionship is more like a partnership or companionship
than a setting with expert/recipient roles. Motivation is an
integral part of changing an individual's behavior and
stimulating the adaptation to good healthy habits. The
four guiding principles of MI are: express empathy,
develop discrepancies, roll with resistance, and support
self-efficacy. MI may be a suitable counseling technique
with which to establish personal relevance and awareness,
so that a positive attitude towards behavioral change is
likely to occur.
PST is a brief, structured psychological intervention, and
can be defined as the self-directed cognitive-behavioral
process by which a person attempts to identify or discover
effective or adaptive solutions for specific problems
encountered in everyday life [29]. The effects of PST have
been proven to be effective in patients with depression
[30,31]. PST may increase a person's ability to solve prob-
lems in a structured way and also result in increasing the
person's self-management. The treatment involves an
active collaboration between participant and therapist,
with the participant taking an increasingly active role in
planning the treatment and implementing activities
between the treatment sessions. The therapist helps partic-
ipants to gain a sense of mastery over their difficulties.
Therefore, PST may be a valuable counseling method. The
treatment can be provided by nurse practitioners, is rela-
tively brief (i.e. only three to six 30-minute sessions are
needed), and is therefore suitable for primary care.
Objectives
The aim of the study is to investigate the effects of a CBP,
compared with providing written information and bro-
chures only. Primary outcomes are the absolute cardiovas-
cular risk and risk of developing T2DM in people who are
at high risk for T2DM and/or CVD. Secondary outcomes
are changes in dietary behavior, physical activity, and
smoking behavior in people who are at high risk for
T2DM and/or CVD.
The cost-effectiveness and cost-utility ratios will also be
assessed.
Methods
Design of the study
The study is designed as a multicenter randomized con-
trolled trial with a two-year follow-up and an economic
evaluation alongside. Participants will be recruited
through a two-step screening procedure (Figure 1), and
those who are eligible and consent will be randomly
assigned to the intervention group or the control group.
The Medical Ethics Committee of the VU University Med-
ical Center in Amsterdam approved the study design, pro-
tocols, information letters and informed consent form.
Setting
The trial will be conducted in the Diabetes Research
Center in Hoorn, in the Netherlands. The intervention
will be provided by nurse practitioners in 12 general prac-
tices in several municipalities in the semi-rural region
(West-Friesland) surrounding the city of Hoorn.
Study population
Twelve thousand inhabitants (men and women) aged 30-
50 living in this region will be invited to participate in a
selective screening procedure. The target group will be
approached, after identification of date of birth and
absence of diabetes or known CVD, from participating
general practices (n = 12).
In the first step of the screening procedure the inhabitants
will receive an invitation to measure their own waist cir-
cumference with a tape measure, according to detailed
instructions. Waist circumference is a widely used indica-
tor of abdominal obesity in population studies. To mini-
mize non-response we will use the modified TailoredPage 3 of 11
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The main elements of this approach are: a brief pre-notice
postcard is sent to each of the sampled persons, and a few
days later a comprehensive and easy to understand invita-
tion is sent, together with the tape measure and a stamped
addressed envelope for the reply. A week after this mail-
ing, another postcard will be sent, in which the respond-
ents are thanked for returning the survey questions and
the non-respondents are asked to complete the waist-
measurement and return it immediately. Four weeks later,
a reminder and a replacement tape measure are sent to the
non-respondents. Abdominal obesity is, in principle,
defined as a waist circumference of 88 cm or more for
women, and 102 cm or more for men [33]. All respond-
ents with a waist circumference of 1 cm under this cut-off
point or above will be invited to participate in the second
step of the screening at the research center. After signing
an informed consent form, this screening will include the
measurement of blood pressure, a blood sample (to deter-
mine total and HDL cholesterol, triglycerides, fasting
plasma glucose, HbA1c), and anthropometric measure-
ments (height, weight, and waist and hip circumference).
In addition, the participants will be given a questionnaire
to fill in at home, including questionnaires about physical
activity, dietary intake, smoking status, determinants of
behavior according to the TPB, quality of life, and depres-
sion.
The 9-year risk of developing diabetes will be estimated
using the risk function derived from data of the Athero-
sclerosis Risk In Communities (ARIC) Study [34], with
ethnicity (black yes/no), parental history of diabetes,
systolic blood pressure, waist circumference and height
(Additional file 1).
The 10-year risk of a fatal cardiovascular disease will be
estimated using the formulae developed by the Systematic
COronary Risk Evaluation (SCORE) project [35], with
gender, smoking status, total cholesterol and systolic
blood pressure (Additional file 2, see Tables 1 &2).
For both scores and for each participant, age will be
extrapolated to 60 years to address the problem of a high
relative but low absolute risk in younger persons. This way
it is possible to flag persons who will become at high
absolute risk [36].
All participants with a minimum risk of 10% for develop-
ing diabetes and/or a minimum risk of 10% for CVD will
be randomly assigned to either the intervention group or
the control group. Exclusion criteria are: inability to com-
municate adequately in the Dutch language and preg-
nancy.
Treatment allocation
An allocation schedule will be drawn up with a computer-
ized random number generator. If there is more than one
participant from a family, the consecutive members of
that family will be allocated to the same group to avoid
contamination. Randomization will be performed by an
independent administrative assistant from the Diabetes
Research Center, who is not involved in the intervention.
Intervention
Intervention group
The participants in the intervention group will receive the
CBP to increase their motivation and ability to change
their dietary pattern, physical activity or smoking behav-
ior. The CBP will be provided by nurse practitioners in the
participating general practices, and will consist of a maxi-
mum of 6 individual 30-minute counseling sessions [37],
followed by 3-monthly booster sessions by phone for a
period of one year. The MI and PST counseling methods
will be used. The counseling sessions are initially given on
a weekly base, but after a few sessions the time between
the sessions is extended to 2/3 weeks, followed by 3-
monthly booster sessions by phone, to act as a reminder
for the participants, to reinforce what they have learned,
and to give them support and feedback.
One of the techniques that is used during MI is reflective
listening, which is applied throughout the whole coun-
seling process. A 'gap' between the participant's current
behavior and the broader goals will be emphasized, culti-
vating motivation for lifestyle change. When the partici-
pant recognizes such discrepancies, a certain level of
discontent arises that makes change more likely to occur.
Discrepancies are emphasized after exploring the partici-
pant's views on their current and future behaviors. Rolling
with resistance invites the participant to consider a new
perspective, instead of having it imposed. Finally, self-effi-
Table 1: Coefficients for Eq. (1)
CHD Non-CHD CVD
α p α p
Low risk Men -22.1 4.71 -26.7 5.64
Women -29.8 6.36 -31.0 6.62
High risk Men -21.0 4.62 -25.7 5.47
Women -28.7 6.23 -30.0 6.42
Table 2: Coefficients for Eq. (2)
CHD Non-CHD
Current smoker 0.71 0.63
Cholesterol (mmol/L) 0.24 0.02
Systolic BP (mmHg) 0.018 0.022Page 5 of 11
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under difficult circumstances, will be supported whenever
possible because it is one of the best predictors of treat-
ment outcome. After the MI counseling the participant is
willing to change and it is time to strengthen the commit-
ment to a plan for lifestyle change using PST. The nurse
practitioner, together with the participant, will make an
implementation plan concerning where, when and how
the behavior changes will take place. This will be done in
the following series of stages [38]: explanation of the
intervention and its rationale, definition and breaking
down of the problem, establishing achievable goals for
problem-solving (achievable goals are SMART goals: Spe-
cific, Measurable, Achievable, Relevant, Timed), generat-
ing multiple possible solutions, evaluating and choosing
the solution, implementing the preferred solution, and
evaluating the outcome.
Each participant will be free to choose which lifestyle
component(s) (smoking, physical activity or diet) he or
she wants to change. The CBP focuses on one problem
area, for which multiple sessions might be needed. MI will
be used first, followed by PST when the participant is
motivated. During the intervention it might be necessary
to revert to MI to motivate the participant again, after
which new goals can be set. The last CBP session is
brought to an end by reviewing and emphasizing the
entire CBP process, with emphasis on the successes
achieved by the participant and implementation of CBP
in the future, independent of the nurse practitioner.
Control group
The participants in the control group will receive written
information about their risk of developing T2DM and
CVD, and existing brochures containing health guidelines
regarding physical activity, a healthy diet, and how to stop
smoking.
Participants with a systolic blood pressure above 160
mmHg and/or hypercholesterolemia (> 8 mmol/L) will
be referred to their GP for additional medication, but will
remain in the study. Participants with a glucose value
above 7.0 mmol/L (confirmed with a second blood sam-
ple) will also be referred to their GP and then excluded for
participation.
Training of nurse practitioners
Prior to the onset of the study, the nurse practitioners will
receive a total of 18 hours of training from experienced
psychologists R. Bes (member of the Motivational Inter-
viewing Network of Trainers (MINT)) and J. Tijhaar (PST
trainer) who are specialized in providing and co-ordinat-
ing CBPs. A treatment manual will be used during the
study to guide the treatment. During the intervention the
nurse practitioners will receive ongoing support during
regular peer supervision meetings. Random CBP sessions
will be tape-recorded to assess the adherence of the nurse
practitioners to the protocol. These tape recordings will
also be used in the peer supervision meetings to provide
ongoing feedback and to increase uniformity of the coun-
seling style among the nurse practitioners.
Blinding
It is impossible to blind the participants and nurse practi-
tioners for the intervention, but the research assistants,
the principal investigator and the GPs will remain blinded
during the entire intervention. This is achieved by
instructing the participants not to communicate about the
intervention with their GP or the medical assistants.
Study duration
The counseling sessions will last for 2-4 months, and the
total intervention period, including booster calls, will be
16 months. Together with an estimated inclusion period
of 8 months, the study itself will take 24 months (2 years).
The measurements will be carried out before the start of
the intervention, and after 6, 12 and 24 months. The base-
line measurements started on February 14th, 2008.
Primary outcome measurements
- Diabetes risk score and cardiovascular risk score.
The risk of developing diabetes will be assessed by means
of a risk function, calculated according to data from the
ARIC Study [34] (see Additional file 1). Absolute cardio-
vascular risk will be assessed with a risk score, calculated
according to the SCORE project [35] (see Additional file
2). For both sores and for each participant, age is set at 60
years.
Secondary outcome measurements
- Dietary behavior, physical activity behavior, and smok-
ing behavior.
- Cost-effectiveness and cost-utility of the CBP.
All relevant direct, indirect and total costs will be
included. Costs related to diabetes, diabetic complica-
tions and cardiovascular disease are considered to be rele-
vant. The costs of the CBP will be assessed using the
bottom-up procedure, based on personnel, material and
housing costs.
Data-collection
Questionnaires
▪ Dietary behavior: An extended and modified version of
the 8-item Food Frequency Questionnaire [39] will be
used to measure the intake of fruit, vegetable, fiber, alco-
hol consumption and (un)saturated fat. Total energy
intake can not be measured with this questionnaire.Page 6 of 11
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Assess Health Enhancing Physical Activity (SQUASH)
[40] will be used to assess physical activity within (A)
commuting activities, (B) leisure time activities, (C)
household activities, and (D) activities at work and
school.
▪ Sedentary behavior during leisure time will be measured
with a subscale of the Activity Questionnaire for Adoles-
cents & Adults (AQUA) [41].
▪ Smoking behavior: Smoking every day/smoking now
and then/never smoked/year of smoking cessation and
pack years (average number packs of 20 cigarettes per day
smoked, multiplied by the number of years as a smoker).
▪ Determinants of behavioral change: A 41-item question-
naire, based on existing TPB questionnaires, will be used
to assess lifestyle-specific behavior with regard to the con-
structs attitude, social norm, self-efficacy and intention to
change. To our knowledge, no suitable validated ques-
tionnaires are available. The theoretical model and ques-
tionnaires in other current studies at the research institute
were used to develop this Determinants of Lifestyle
Behavior Questionnaire (DLBQ).
▪ Quality of life will be assessed with the EuroQol (EQ-
5D) [42,42,43].
▪ Compliance: The number of CBP sessions attended will
be registered, and compliance is considered adequate if at
least two sessions are attended.
Cost-diaries
▪ Direct health care, non-health care costs and indirect
non-health care costs will be recorded in cost-diaries that
will be sent via e-mail to the participants in 3-monthly
time-intervals. Printed cost-diaries will be sent to partici-
pants who do not have access to or dislike the Internet.
Direct health care costs will include costs of the CBP, visits
to the GP, medical specialists, therapists, dieticians, med-
ication, and hospitalization. Direct non-health care costs
will include the costs of over-the-counter medication,
physical activity programs, travel time, and waiting time.
Indirect costs will include the costs of absence from paid
and unpaid work.
▪ Co-interventions: In both groups, any co-intervention
will be reported in the cost-diaries.
Physical measurements
▪ Anthropometric measurements: Weight, height, and
waist-hip circumferences. Body weight and height will be
measured to calculate the BMI (weight divided by height
squared). Height will be measured to the nearest 0.1 cm
without shoes, whereas weight will be measured to the
nearest 0.5 kg, wearing indoor clothing and no shoes.
Waist circumference will be measured at the level midway
between the lowest rib margin and the iliac crest, and the
hip circumference at the widest level over the greater tro-
chanters.
▪ Systolic and diastolic blood pressure will be measured
after 5 minutes of rest, in a seated position, with the Col-
lin Press Mate (BP-8800, Komaki-City).
▪ Laboratory tests: Fasting blood samples will be taken
(venapunction) to measure glucose, Hb1Ac, total choles-
terol, HDL-cholesterol, and triglycerides.
Process evaluation
A process evaluation will be carried out to study the effec-
tive and ineffective parts of the intervention. In the second
questionnaire the participants of the intervention group
are asked to score three items regarding their satisfaction
with the intervention on a 4-point Likert scale, and indi-
cate whether or not they are changing their lifestyle as
planned in the program (yes/no). The nurse practitioners
are asked to give their opinion on a 4-point Likert scale
regarding five statements (i.e. about the MI and PST train-
ing and their confidence in providing the counseling ses-
sions), and on two open-ended questions about their
perception of the effectiveness of the training. These state-
ments are scored twice: directly after the training session
and again after the recruitment period (about eight
months later). The quality of the nurse practitioner MI
will be assessed according to the Motivational Interview-
ing Treatment Integrity (MITI), a behavioural coding sys-
tem that will be applied to the tape-recordings of the
counseling sessions [44]. The results will be linked with
the risk scores of the participants after one year. This will
make it possible to evaluate the effect of the counseling
skills of the nurse practitioners on patient outcomes.
Sample size
In a Dutch working population of overweight people
(BMI ≥ 25), which consisted of both males and females,
the standard deviation of the ARIC score was found to be
8.11 [45]. For a two-sided detection of a 5% between-
group difference in cardiovascular risk score, standardized
at 60 years of age, with an alpha of 0.05 and a power of
90%, in the present study 120 participants will be needed
in the intervention group and 120 in the control group.
Assuming that 40 participants per collaborating GP are
recruited, and each participant is randomized independ-
ently, this is feasible. We expect a response of approxi-
mately 65% in the first step of the screening, 20% of
which will meet the abdominal obesity criterion [46,47].
Of those who meet this criterion, we expect that at leastPage 7 of 11
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the RCT (Figure 1).
A multilevel analysis is performed to be able to adjust for
the clustering of observations within practices. To be able
to perform stratified and multivariable analyses, and tak-
ing loss to follow-up into account, larger numbers will be
needed. A total of 600 (i.e. 300 in the intervention group
and 300 in the control group) is expected to suffice.
Analyses
Descriptive statistics (means ± SD, or median and inter-
quartile ranges, as appropriate) will be used to describe
the entire study sample with regard to demographics,
physical measurements and baseline lab values. The anal-
yses will be conducted according to the intention to treat
principle. Multilevel analyses will be performed to adjust
for the clustering of observations of participants receiving
care from the same nurse practitioner, and for repeated
measurements within one patient. Linear and logistic
regression models will be used to examine the effect of the
intervention on each of the outcome measurements. Dif-
ferences in changes between groups will be calculated
with 95% confidence intervals. If there are any relevant
differences in baseline measurements between the two
groups, we will adjust the outcome for these factors (i.e.
age, gender, ethnicity, BMI at the start of study, level of
education, depression, smoking, number of sessions
attended). Separate analyses of effect modifiers (i.e. gen-
der, age) will be performed in order to gain a better under-
standing as to who benefits most from the intervention.
Separate analyses of effect modifiers and mediators will be
conducted in order to gain a better understanding as to
who benefits most from the intervention
Economical evaluation
An economic evaluation will be performed after 24
months from the societal perspective and from the health
insurance perspective. Differences in mean costs between
the two groups will be presented with 95% confidence
intervals, estimated with bootstrapping methods. Incre-
mental cost-effectiveness ratios (ICERs) will be calculated
by dividing the incremental mean costs by the incremen-
tal mean effects for: a) reduction in the risk of developing
diabetes based on the ARIC score, b) reduction in the risk
of future cardiovascular disease based on the SCORE, and
c) quality-adjusted life years (QALYs) based on the Euro-
Qol. The 'Dutch EQ-5D tariff' [48] will be used to calcu-
late utilities.
Bootstrapping methods will be used to derive cost-effec-
tiveness planes and acceptability curves.
Discussion
This article presents a detailed description of an RCT,
designed with the aim to investigate the effectiveness of a
CBP to improve lifestyle behavior and reduce T2DM and
CVD risk in a high-risk population. This will provide
researchers, health care providers and policy makers the
opportunity to critically review the methodological qual-
ity, the background theory and the practical issues of the
RCT. An innovative and key element of this trial is that the
participants will be self-empowered to accomplish a long-
lasting change in their lifestyle. We expect that the specific
counseling methods (MI and PST) will induce an effec-
tive, sustained reduction in T2DM and CVD risk. Both
counseling methods are practical, evidence-based tools.
The combination of MI and PST, in particular, is used
before [49], but never in preventive trials. Combining the
two counseling methods may be effective because PST can
help to resolve the ambivalence created with MI. By doing
so, practical tools to sustained pro-active behavioral
change are handed to the participants, who become aware
of their unhealthy behavior and are intrinsically moti-
vated to change. The participants will be free to choose
which lifestyle component(s) (smoking, physical activity
or diet) they want to change. Offering different behavioral
alternatives to achieve the participant's goals may posi-
tively affect compliance and long-term success.
After the counseling the participants will receive continu-
ing support in the form of 3-monthly booster sessions by
phone, which will help them to sustain behavioral
changes.
There are some limitations in the study design. Critics
may raise concerns about the use of the DLBQ to assess
determinants of change in lifestyle behavior, because this
questionnaire has not been validated. We developed this
questionnaire by using several questionnaires of col-
leagues in the field since we were not able to find a vali-
dated questionnaire to assess determinants of behavior.
Another concern could be the benefit participants in the
intervention group may have from the extra attention they
get. However, attention alone is unlikely to result in
behavioral change. Furthermore, it has been demon-
strated that MI and PST are significantly more effective
than attention alone [50-52].
Non-respondents are a potential threat to the external
validity of a study. Therefore we chose to approach poten-
tial participants with correspondence at multiple
moments, as described by Dillman et. al. [32]. The inter-
vention will take place in close proximity to the homes of
the participant, and this could reduce barriers for partici-
pation. Furthermore, two bicycles will be raffled among
those who respond to the first screening step. Despite of
these measures, we expect that participants who agree toPage 8 of 11
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change their lifestyle than the non-respondents [53].
However, because the participants will be randomized,
this will be the case in both groups. Having a population
of motivated participants might decrease the drop-out
percentage.
A strength of the study design is its focus on lifestyle
dependent risk factors that are associated with both T2DM
and CVD. To select people who are at risk of these dis-
eases, self-measured waist circumference is used as a first
screening step, which is a simple and practical method.
Another strength is the careful monitoring of the interven-
tion by providing standardized training for the nurse prac-
titioners and feedback on the counseling sessions by
means of tape recordings.
If this intervention has strong positive effects, the CBP
could be widely implemented. The process evaluation of
our intervention will come up with barriers and facilita-
tors that can be used for the implementation strategy.
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